ArticleMolecular medicine (Cambridge, Mass.)2025
PELI2 inhibits colorectal cancer development through MAPK signaling pathway.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pomegranate peel-derived exosome-like nanoparticles: A discarded treasure trove for colorectal cancer treatment.Oncology letters · 2026Article
- Pellino ubiquitin ligases: double-edged swords in hematologic malignancies-from oncogenic stabilizers to therapeutic vulnerabilities.Journal of cancer research and clinical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Colorectal cancer is one of the most common malignant tumors worldwide. Colorectal cancer has a poor survival rate because it tends to metastasise to the liver and other organs. PELI2, an E3 ubiquitin ligase, is down-expressed in a variety of tumors. However, the role of PELI2 in colorectal cancer has not been revealed. In the present study, we found that expression level of PELI2 were reduced significantly in colorectal tumors compared with normal tissues. Patients with low level of PELI2 expression tended to have poor prognosis. Moreover, PELI2 decreased the proliferation, migration and anti-apoptosis of colorectal cancer cells in vitro. We also constructed xenograft tumor model to verify colorectal tumor growth slowed down after PELI2 overexpression. Transcriptome analysis suggested that PELI2 suppressed colorectal cancer progression via the MAPK signaling pathway. In brief, our study shows that PELI2 inhibits colorectal cancer development by MAPK signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.